Breakthroughs that
See news releases about Etira, our stellar team,
DECRYPTING THE OLIGO-BENZAMIDE PLATFORM
NewsDallas, TX – June 15, 2024: The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions. Herein,…
ERX-315 SUBMITTED FOR HREC APPROVAL
NewsDallas, TX – May 14th, 2024: Etira is pleased to announce the submission of the regulatory documents for approval of administration of its breakthrough oncology drug ERX-315 to the Human Research Ethics Committee (HREC) in Australia. This…
ERX-208 potency in Ovarian Cancer
NewsSan Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity…
Targeting LIPA in ovarian cancer
NewsDallas, TX. January 24, 2024: We are pleased to present a manuscript in Cancers from the laboratory of Etira founder Dr. Ratna Vadlamudi. The data presented show that ERX-41 targets LIPA in ovarian cancer and is effective against all 4 subtypes…
ERX-315 introduced at SABCS 2023
NewsSan Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple forms…
Where to find us
Boston Office:
75 Kneeland Ave, 14th Floor
Boston. MA. 02111
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247